Diagnostic News and Research

RSS

New FDR D-EVO flat panel cassette available for clinical environment

Imaging facilities looking to convert existing analog x-ray rooms to digital can now benefit from the ease-of-use and exceptional image quality of the FDR D-EVO flat panel cassette from FUJIFILM Medical Systems U.S.A., Inc. Now FDA 510(k) cleared, the FDR D-EVO™ makes it more convenient to transition to DR with its seamless retrofit that enables facilities to insert the DR detector directly into the existing x-ray table or wall stand without modification.

21 Jul 2010

Saladax Biomedical achieves ISO 13485:2003 certification

Saladax Biomedical, Inc. announced today that it has achieved ISO 13485:2003 certification for the design, manufacture and distribution of in vitro diagnostic medical devices in the area of clinical chemistry. Saladax's Bethlehem, PA facility was certified after a comprehensive audit of the Company's quality systems was conducted by KEMA, an internationally recognized standards registrar.

21 Jul 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Neogen fiscal 2010 net income increases 26% to $17.5M

Neogen Corporation announced today that its net income for its 2010 fiscal year, which ended May 31, increased 26% from the previous year to $17,521,000. Net income in the fiscal year increased to $0.76 per share, compared to the prior year's $0.61, adjusted for a 3-for-2 stock split that was effective Dec. 15, 2009.

20 Jul 2010

Meridian Bioscience completes acquisition of Bioline group of companies

Meridian Bioscience, Inc., Cincinnati, Ohio announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

20 Jul 2010

Quantitative capabilities of Helicos' single-molecule sequencing technology demonstrated

Helicos BioSciences Corporation today announced a publication entitled "Amplification-free digital gene expression profiling from minute cell quantities" appearing on line in Nature Methods co-authored by Dr. Daniel A. Haber and colleagues from Massachusetts General Hospital. The paper demonstrates the quantitative capabilities of Helicos' single-molecule sequencing technology and its potential to reveal important genomic differences when minimal numbers of cells are available for analysis.

20 Jul 2010

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

WHO announces new approaches to HIV prevention and treatment among children

Efforts worldwide on access to treatment for children with HIV have reached a new milestone, with 355 000 children receiving life-saving HIV treatment at the end of 2009, compared to 276 000 at the end of 2008; but many more lives could be saved if more infants started on medication earlier according to new recommendations from the World Health Organization (WHO).

20 Jul 2010

Cardiac Science addresses outstanding issues relating to corrective AED field action with FDA

Cardiac Science Corporation, a global leader in automated external defibrillator and diagnostic cardiac monitoring devices, announced it has addressed outstanding issues with the Food and Drug Administration relating to the corrective AED field action announced on November 13, 2009.

20 Jul 2010

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

MDMA (-3,4-methylenedioxymethamphetamine, also known as Ecstasy), may one day offer hope for individuals with posttraumatic stress disorder (PTSD), even people for whom other treatments have failed. Clinical trial results out today in the Journal of Psychopharmacology, published by SAGE, suggests that MDMA can be administered to subjects with PTSD without evidence of harm and could offer sufferers a vital window with reduced fear responses where psychotherapy can take effect.

20 Jul 2010

Plea for Federal legislation to ban mercury in vaccines, prevent autism

Two papers in this week's neuroscience journal Acta Neurobiologiae Experimentalis point to vaccines and heavy metals including mercury as causes of the alarming rise in autism. The Centers for Disease Control now estimate autism to affect one in 110 children, up 40% from just a few years ago.

20 Jul 2010

Low radiation CT scans now at Saint Francis Hospital

Patients requiring a CT scan at Saint Francis Hospital will now be exposed to up to 40 percent less radiation than traditional CT scans. The hospital has acquired state-of-the-art GE™ scanning equipment featuring Adaptive Statistical Iterative Reconstruction (ASiR) that uses an advanced image reconstruction technique that makes it possible to dramatically reduce radiation dose without compromising image quality.

20 Jul 2010

Corgenix, ELITech establish broad strategic alliance

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents, today announced a broad strategic alliance.

19 Jul 2010

Microarrays acquired from Vanderbilt University

Microarrays, Inc. (MI), an innovator of array-based technologies for biological research, detection and diagnostics, today announced that the company's management team and a group of independent investors have purchased MI from Vanderbilt University. The new company structure will allow MI to more quickly and nimbly respond to client's rapidly expanding needs, especially within the diagnostic and health care arenas.

19 Jul 2010

Biosystems International closes EUR2.1 million funding round

Biosystems International (BSI) SAS, Biotech Leader in the Development of Monoclonal Antibody Based Diagnostics for Cancer, Announced Today That it has Closed a Round of Funding Amounting to EUR2.1 Million ($2.7 Million).

19 Jul 2010

Low-dose method of performing CT heart scans developed at Porter Adventist Hospital

As warnings and concern increase over the health risks of commonly used scanning tests involving high doses of radiation, radiologists and scientists are seeking ways to improve the safety of the tools they use in diagnosing disease.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

Lab-on-Bead technology helps researchers cut years from drug development

New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.

16 Jul 2010

Philadelphia to host 52nd annual meeting of American Association of Physicists in Medicine

Next week the city of Philadelphia will host the 52nd annual meeting of the American Association of Physicists in Medicine (AAPM), the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology.

16 Jul 2010